A phase 3, randomized, double-blind, multicenter study of talabostat and pemetrexed [Alimta; Eli Lilly] vs. pemetrexed and placebo in patients with advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 19 Sep 2007

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pemetrexed (Primary) ; Talabostat (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Sponsors Point Therapeutics

Most Recent Events

22 May 2007 Status change
10 Feb 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight